ES2149174T3 - Un sistema de vacunacion de una sola dosis. - Google Patents

Un sistema de vacunacion de una sola dosis.

Info

Publication number
ES2149174T3
ES2149174T3 ES92907229T ES92907229T ES2149174T3 ES 2149174 T3 ES2149174 T3 ES 2149174T3 ES 92907229 T ES92907229 T ES 92907229T ES 92907229 T ES92907229 T ES 92907229T ES 2149174 T3 ES2149174 T3 ES 2149174T3
Authority
ES
Spain
Prior art keywords
water
biologically active
active material
insoluble
single dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92907229T
Other languages
English (en)
Inventor
Ian George Barr
William James Thiel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Ltd
Monash University
Original Assignee
CSL Ltd
Monash University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Ltd, Monash University filed Critical CSL Ltd
Application granted granted Critical
Publication of ES2149174T3 publication Critical patent/ES2149174T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA INVENCION PRESENTA UN IMPLANTE FARMACEUTICO O VETERINARIO, QUE CUANDO SE ADMINISTRA PARENTERALMENTE LIBERA UN IMPULSO DE AL MENOS UN MATERIAL BIOLOGICAMENTE ACTIVO EN UN INTERVALO DE TIEMPO CONTROLABLE TRAS LA IMPLANTACION. EL IMPLANTE CONTIENE EL MATERIAL BIOLOGICAMENTE ACTIVO; UN EXCIPIENTE QUE CONTIENE AL MENOS UN MATERIAL SOLUBLE EN AGUA Y AL MENOS UN MATERIAL INSOLUBLE EN AGUA; UN REVESTIMIENTO DE PELICULA POLIMERICA ADAPTADO PARA ROMPERSE EN UN PERIODO DE TIEMPO PREDETERMINADO DESPUES DE LA IMPLANTACION Y EN DONDE LOS EXCIPIENTES Y LOS POLIMEROS SON BIOCOMPATIBLES. EL MATERIAL BIOLOGICAMENTE ACTIVO SE SELECCIONA DEL GRUPO QUE CONSISTE EN ANTIGENOS, ANTICUERPOS, HORMONAS, PROMOTORES DEL CRECIMIENTO, ANTIBIOTICOS, NUTRIENTES, MINERALES Y VITAMINAS. PREFERENTEMENTE, EL EXCIPIENTE CONTIENE UNA COMBINACION DE DOS O MAS MATERIALES SOLUBLES EN AGUA E INSOLUBLES EN AGUA.
ES92907229T 1991-03-26 1992-03-25 Un sistema de vacunacion de una sola dosis. Expired - Lifetime ES2149174T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPK526891 1991-03-26
PCT/AU1992/000124 WO1992017165A1 (en) 1991-03-26 1992-03-25 A single dose vaccination system

Publications (1)

Publication Number Publication Date
ES2149174T3 true ES2149174T3 (es) 2000-11-01

Family

ID=3775296

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92907229T Expired - Lifetime ES2149174T3 (es) 1991-03-26 1992-03-25 Un sistema de vacunacion de una sola dosis.

Country Status (8)

Country Link
US (1) US5593697A (es)
EP (1) EP0576522B1 (es)
AT (1) ATE194910T1 (es)
CA (1) CA2106952C (es)
DE (1) DE69231291T2 (es)
ES (1) ES2149174T3 (es)
NZ (2) NZ286242A (es)
WO (1) WO1992017165A1 (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358502A (en) * 1993-02-25 1994-10-25 Pfizer Inc PH-triggered osmotic bursting delivery devices
CA2158651C (en) * 1993-03-29 2009-09-01 David S. Roberts Multicomponent clostridial vaccines using saponin adjuvants
NZ281797A (en) * 1994-02-18 1997-04-24 Innovac Co Inoculation of animals by inserting dried pelleted biological materials into the animal's ear
CA2193806A1 (en) * 1994-06-22 1995-12-28 Michael Cardamone Controlled release device and method
FR2723536A1 (fr) * 1994-08-11 1996-02-16 Seth Pawan Composition permettant une liberation selective d'un principe actif
AUPM897594A0 (en) * 1994-10-25 1994-11-17 Daratech Pty Ltd Controlled release container
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US6143037A (en) * 1996-06-12 2000-11-07 The Regents Of The University Of Michigan Compositions and methods for coating medical devices
US6140475A (en) 1997-04-11 2000-10-31 Altus Biologics Inc. Controlled dissolution crosslinked protein crystals
ES2320603T3 (es) 1997-07-30 2009-05-25 Emory University Sistemas de expresion, vectores, adn, proteinas de mineralizacion osea novedosos.
BR9815240A (pt) * 1997-10-09 2001-10-30 Perio Prod Ltd Sistema de fornecimento de medicamentogastrointestinal de liberação total retardada
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
TR200003225T2 (tr) * 1998-03-02 2001-02-21 Applied Vaccine Technologies Copr. Bağışıklık tepkisini modüle etmek için yöntemler ve araçlar
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
US20030099682A1 (en) * 1998-11-20 2003-05-29 Francis Moussy Apparatus and method for control of tissue/implant interactions
EP1130996B1 (en) 1998-11-20 2005-04-13 The University of Connecticut Generic integrated implantable potentiostat telemetry unit for electrochemical sensors
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US20040121014A1 (en) * 1999-03-22 2004-06-24 Control Delivery Systems, Inc. Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US7030097B1 (en) 1999-07-14 2006-04-18 Cornell Research Foundation, Inc. Controlled nucleic acid delivery systems
HUP0202537A3 (en) 1999-08-24 2004-05-28 Teva Pharma A vaccine composition and method of using the same
US6592869B2 (en) 1999-08-24 2003-07-15 Teva Pharmaceutical Industries, Ltd. Vaccine composition and method of using the same
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
DE10035156A1 (de) * 2000-07-19 2002-02-07 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel
US7575780B2 (en) * 2000-08-07 2009-08-18 Orthogen Llc Method for manufacturing particles for use in forming a resorbable implant for stimulating bone growth
GB0025208D0 (en) 2000-10-13 2000-11-29 Euro Celtique Sa Delayed release pharmaceutical formulations
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
AU2003232078A1 (en) 2002-05-06 2003-11-17 Massachusetts Institute Of Technology Diffusion-controlled dosage form and method of fabrication including three dimensional printing
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
US20050152939A1 (en) * 2002-05-22 2005-07-14 Bunt Craig R. Delivery technology
WO2003101483A1 (en) * 2002-05-31 2003-12-11 Solux Corporation Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
KR100628263B1 (ko) * 2002-08-21 2006-09-27 엘지.필립스 엘시디 주식회사 액정표시소자
US7452350B2 (en) * 2003-07-09 2008-11-18 Yeakley Rourke M Pre-dosed oral liquid medication dispensing system
DK2384753T3 (en) 2003-08-29 2016-04-11 Brigham & Womens Hospital Hydantoin derivatives as inhibitors of cell necrosis
US20060280795A1 (en) * 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
EP1924211B1 (en) 2005-08-23 2019-12-18 Smith & Nephew, Inc. Telemetric orthopaedic implant
US20070190157A1 (en) * 2006-01-20 2007-08-16 Monosoirx, Llc. Film lined packaging and method of making same
US9849216B2 (en) * 2006-03-03 2017-12-26 Smith & Nephew, Inc. Systems and methods for delivering a medicament
CA2664615A1 (en) * 2006-09-29 2008-04-10 Monosol Rx, Llc Film embedded packaging and method of making same
BRPI0923126A2 (pt) 2008-12-23 2021-09-08 President And Fellows Of Harvard College Compostos inibidores de molécula pequena de necroptose, uso e composição compreendendo os mesmos e método de diminuir necroptose
WO2011079232A1 (en) * 2009-12-23 2011-06-30 Psivida Us, Inc. Sustained release delivery devices
US8109917B2 (en) * 2010-01-18 2012-02-07 Rourke M. Yeakley Twistable medication dispensing system
US8206368B2 (en) * 2010-01-18 2012-06-26 Rourke M. Yeakley Multi-chamber mixture dispensing system
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
US20140377320A1 (en) 2011-12-22 2014-12-25 Chuv, Centre Hospitalier Universitaire Vaudois Selective Plasma Activation for Medical Implants and Wound Healing Devices
CN104136004B (zh) 2012-02-22 2018-03-06 达切斯内公司 多西拉敏和吡哆醇和/或其代谢物或盐的制剂
US9717583B2 (en) 2014-03-13 2017-08-01 Cell and Molecular Tissue Engineering, LLC Sensors, cannulas, collars and coated surgical mesh, and corresponding systems and methods
EP2968162B1 (en) * 2013-03-15 2020-12-02 Incube Labs, Llc Multi-stage biodegradable drug delivery platform
EP2968276A4 (en) 2013-03-15 2017-02-15 President and Fellows of Harvard College Hybrid necroptosis inhibitors
ES2670619T3 (es) 2013-07-22 2018-05-31 Duchesnay Inc. Composición para la gestión de náuseas y vómitos
WO2016094846A1 (en) 2014-12-11 2016-06-16 President And Fellows Of Harvard College Inhibitors of cellular necrosis and related methods
JP7653218B2 (ja) 2016-05-05 2025-03-28 アクエスティブ セラピューティクス インコーポレイテッド 送達増強エピネフリン組成物
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US12465564B2 (en) 2021-10-25 2025-11-11 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment
CN120241585A (zh) * 2025-05-07 2025-07-04 长江大学 一种疫苗缓释埋植体及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3247066A (en) * 1962-09-12 1966-04-19 Parke Davis & Co Controlled release dosage form containing water-swellable beadlet
FR2454804B1 (fr) * 1979-04-26 1986-11-21 Sanofi Sa Medicament a base de dihydroergotoxine et son procede de preparation
ZA86252B (en) * 1985-01-30 1986-09-24 Warner Lambert Co Coated dosage forms
EP0212745B1 (en) * 1985-08-16 1991-04-10 The Procter & Gamble Company Drug particles having constant release
DE3684446D1 (de) * 1985-12-28 1992-04-23 Sumitomo Pharma Arzneimittel mit verzoegerter stossweiser freisetzung.
WO1987006828A1 (en) * 1986-05-16 1987-11-19 The State Of Victoria Biocompatible implants
ATE90203T1 (de) * 1989-03-17 1993-06-15 Pitman Moore Inc Kontrollierte, verzoegerte wirkstofffreisetzung von makromolekularen proteinen.
US5026559A (en) * 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
EP0408496A3 (en) * 1989-07-12 1992-07-01 Ciba-Geigy Ag Solid dosage form for pharmaceutical substances
JPH03197421A (ja) * 1989-12-26 1991-08-28 Takeda Chem Ind Ltd 徐放性錠剤
US5091185A (en) * 1990-06-20 1992-02-25 Monsanto Company Coated veterinary implants

Also Published As

Publication number Publication date
US5593697A (en) 1997-01-14
NZ286242A (en) 1997-11-24
ATE194910T1 (de) 2000-08-15
NZ242065A (en) 1996-06-25
CA2106952A1 (en) 1992-09-27
EP0576522B1 (en) 2000-07-26
EP0576522A4 (en) 1994-06-01
EP0576522A1 (en) 1994-01-05
WO1992017165A1 (en) 1992-10-15
DE69231291D1 (de) 2000-08-31
DE69231291T2 (de) 2001-01-18
CA2106952C (en) 2003-01-21

Similar Documents

Publication Publication Date Title
DE69231291D1 (de) Impfsystem mit einer einzeldosis
DE60005049D1 (de) Bioabsorbierbare arzneimittelabgabevorrichtung
US3765414A (en) Drug release system
Langer Polymer-controlled drug delivery systems
Kitchell et al. [32] Poly (lactic/glycolic acid) biodegradable drug—polymer matrix systems
NO884474D0 (no) Implanterbart, biologisk nedbrytbart virkestoff-frigjoeringssystem.
GB1462958A (en) Biodegradable implantable drug delivery device and process for preparing and using the same
ES2113906T3 (es) Composiciones polimericas utiles como implantes con administracion controlada.
UA35569C2 (uk) Композиція для пролонгованого і контрольованого вивільнення пептидної лікарської речовини і спосіб її одержання, спосіб приготування суспензії, що призначена для парентерального введення
DK0862416T3 (da) Ikke-polymert indgivelsessystem med forhalet frigørelse
AU7465087A (en) Controlled release bioerodible drug delivery system
EP0641219A1 (en) Biodegradable bursting release system
HUP9904174A2 (hu) Bőrön át történő adagoláshoz szánt gyógyszerkészítmények
DE69534080D1 (de) Kontrollierte, lokale verabreichung von chemotherapeutischen wirkstoffen zur behandlung von festen tumoren
GB1560017A (en) Antibiotic-containing composition
ES2074050T3 (es) Sistema de liberacion.
BR9707637A (pt) Sistema implantável implante destinado a administração subcutânea ou local e conjunto farmacêutico
DE69519685D1 (de) Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
US3796217A (en) Drug release system
Benagiano et al. Biodegradable systems for the sustained release of fertility-regulating agents
ATE295157T1 (de) Mittel zur transdermalen verabreichung von arzneistoffen
AU5789490A (en) Intermittent release dosage form
CA2487968A1 (en) A novel drug dosing regimen
SE8601563D0 (sv) Matrismaterial, forfarande for framstellning derav och anvendning derav
ATE323527T1 (de) Verpackung und verfahren zur handhabung von festen arzneimitteldosen

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 576522

Country of ref document: ES